Amadeus Capital Partners has bought a stake in the Amgen and Illumina-backed company through a secondary transaction, valuing it at around $2.4bn.

Cambrian Biopharma has backed a round that will go toward further developing Vita’s lead candidate, VTA-110, for muscular dystrophy treatments.

The SEB-backed tranche has helped the Stockholm spinout lift the round to $13.3m, which will be used to conduct a proof-of-concept run.

Several financial services firms have contributed to a $25.5m round for the contract review technology developer.

Amadeus Capital Partners has bought a stake in the University of Oxford spinout through a secondary transaction, valuing it at around $2.4bn.

The Johns Hopkins University spinout’s latest funding will go toward further developing its lead candidate, VTA-110, for muscular dystrophy treatments.

The Industrifonden-led tranche has helped the Stockholm spinout lift the round to $13.3m, which will be used to conduct a proof-of-concept run.

The Kyoto University spinout backed by the institution’s i-Cap fund has secured $25.5m in funding from returning investors.

DivcoWest and RXR Realty have contributed to a $41m series A round for the mobility technology developer that has now raised more than $60m.

Investments from BP and Chevron will support the thermal energy technology developer’s goal of supplying 10 million homes’ worth of power by the end of the decade.